8-K: Envoy Medical Reports Progress on Fully Implanted Cochlear Implant and Second Quarter 2024 Financial Results

Envoy Medical is advancing its fully implanted Acclaim cochlear implant, with positive early study results and plans to begin a pivotal clinical trial by the end of 2024, while reporting a slight increase in revenue for the second quarter.

Summary

• Envoy Medical announced its second quarter 2024 results, highlighting progress with its Acclaim cochlear implant.
• All three participants in the Early Feasibility Study (EFS) at Mayo Clinic have completed their 18-month follow-up, reporting daily use of the device and improvements in quality-of-life scores.
• The company has addressed internal system noise issues with the Acclaim device, improving the signal-to-noise ratio.
• The AcclaimPlus listening condition, where patients use a hearing aid in conjunction with the implant, shows promising preliminary results.
• Envoy Medical aims to submit an Investigational Device Exemption (IDE) application in the coming months and hopes to begin a pivotal clinical trial by the end of 2024.
• Commercialization of the Acclaim device is targeted for the end of 2026.
• Second quarter revenue was $68 thousand, a slight increase from $63 thousand in the same period of 2023, primarily due to Esteem FI-AMEI unit sales.
• Research and development expenses increased to $2.6 million, up from $2.153 million in the same quarter of 2023, due to increased headcount and contractors.
• The company had approximately $1.7 million in cash and cash equivalents as of June 30, 2024.
• The Esteem FI-AMEI is the only FDA-approved fully implanted hearing device for adults with moderate to severe sensorineural hearing loss.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. There is positive progress in the clinical trials and product development, but the financial results are weak with a low cash balance and significant losses. The company is still in the early stages of commercialization and faces significant risks.

Positives

• The Early Feasibility Study (EFS) participants are showing positive results with the Acclaim cochlear implant.
• The company has successfully addressed the system noise issue, improving the device's performance.
• The AcclaimPlus listening condition presents a potential benefit for patients.
• The company is on track to submit an IDE application and begin a pivotal clinical trial by the end of 2024.
• The Esteem FI-AMEI is the only FDA-approved fully implanted hearing device.

Negatives

• The company experienced increased cost of goods sold due to manufacturing and material scrap for the Esteem FI-AMEI product.
• The company has a low cash balance of approximately $1.7 million as of June 30, 2024.
• The company reported a net loss of $3.947 million for the quarter ended June 30, 2024.
• There were two revision surgeries required for two participants in the EFS to replace the Acclaim battery with an updated design.

Risks

• The Acclaim cochlear implant is still an investigational device and subject to regulatory approval.
• The company's financial position is weak with a low cash balance.
• The company is subject to risks related to the medical device industry, regulatory processes, and clinical development.
• There are risks associated with competition in the medical device industry.
• The company is subject to risks related to supply chain disruptions and production capabilities.

Future Outlook

Envoy Medical is focused on advancing the Acclaim cochlear implant through clinical trials and regulatory approval, with a goal of commercialization by the end of 2026. The company is also working to secure reimbursement for the Esteem FI-AMEI device.

Management Comments

• We are pleased with the steady progress that Envoy Medical has made this quarter and year-to-date in advancing our goal of becoming a leading cochlear implant company, commented Brent T. Lucas, Envoy Medicals Chief Executive Officer.
• We believe the results of our Early Feasibility Study justify further study of our breakthrough fully implanted cochlear implant and intend to submit an IDE application to begin a Pivotal Clinical Trial in the coming months.

Industry Context

Envoy Medical is operating in the competitive hearing health industry, focusing on fully implanted devices. The company's Acclaim cochlear implant aims to differentiate itself through its unique design and potential for integration with other electronic devices. The company is competing with established players in the cochlear implant market, as well as companies developing other hearing solutions.

Comparison to Industry Standards

• Cochlear Limited (COH.AX) is a major competitor in the cochlear implant market, with a well-established product line and global presence. Envoy Medical's Acclaim device is attempting to differentiate itself with a fully implanted design, which is not a standard feature of Cochlear's products.
• Advanced Bionics, a subsidiary of Sonova, is another key competitor in the cochlear implant space. Their products are also not fully implanted, giving Envoy Medical a potential advantage if they can successfully commercialize the Acclaim device.
• The reported revenue of $68 thousand is very low compared to the revenue of established players in the industry, highlighting the early stage of Envoy Medical's commercialization efforts.
• The increase in R&D expenses to $2.6 million is typical for a company in the clinical development phase, but the company's low cash balance of $1.7 million is a concern compared to the financial resources of larger competitors.

Stakeholder Impact

• Shareholders may be concerned about the company's low cash balance and significant losses.
• Employees may be impacted by the company's financial situation and future plans.
• Patients with hearing loss may benefit from the development of the Acclaim cochlear implant.
• Suppliers may be impacted by the company's financial situation and production plans.
• Creditors may be concerned about the company's ability to repay its debts.

Next Steps

• The company plans to submit an Investigational Device Exemption (IDE) application in the coming months.
• The company aims to begin a pivotal clinical trial by the end of 2024.
• The company will provide more details on the study design once approval is granted to begin the study.
• The company is targeting commercialization of the Acclaim device by the end of 2026.

Key Dates

Keywords

cochlear implant, hearing loss, medical device, fully implanted, clinical trial, Acclaim, Esteem, sensorineural, FDA, IDE